Before the annual congress of the European Society for Medical Oncology began in Barcelona, clinicians held a press ...
Nuvalent Inc. followed positive data during the European Society for Medical Oncology (ESMO) meeting with an upsized $500 million public offering. The Cambridge, Mass.-based firm is selling 5 million ...
The European Organization for Research and Treatment of Cancer (EORTC), a network of 3,800 members across 50 countries, is ...
El Mundo on MSN5d
A drug combination that prevents relapses in women with the most common breast cancer: "It is a significant advancement because they are cured"The use of a molecule and hormonal therapy reduces the risk of relapse by 28.5% after surgery in a broad population of patients with luminal breast tumors. "Early detection and the use of treatments ...
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: ...
The European Society for Medical Oncology (ESMO) is calling on all actors of the oncology community to commit to improving the well-being of the cancer workforce and join in 11 actions outlined in a ...
Initial results from dose escalation in the first in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced solid tumours known to express Claudin-6 (CLDN6) ...
A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentation has concluded. About BioAtla®, Inc.
Obesity is a key factor in cardiovascular disease, prompting the ESC to recommend comprehensive strategies for prevention and ...
Initial results from dose escalation in the first-in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback